Focus: Infection Control

Widow sues Olympus over scope-related superbug outbreak

Case is the first to go to trial in the U.S. stemming from a series of superbug outbreaks


A Seattle widow's case against Olympus Corp is the first to go to trial in the U.S. stemming from a series of deadly superbug outbreaks across the country that were linked to contaminated medical scopes, according to an article on the Kaiser Health News website.
 
She is suing Olympus Corp., claiming that one of its tainted devices caused the infection that led to her husband’s death in August 2013. 
 
According to her suit, Olympus executives remained silent for too long about a design flaw that hindered cleaning of these reusable scopes.
 
The Seattle case may serve as a bellwether for future litigation, the article said. It also offers a preview of the evidence federal prosecutors in New Jersey could use against Olympus in a possible criminal case.
 
 
 
 
 


June 26, 2017


Topic Area: Infection Control


Recent Posts

17 Million Patient Records Stolen in PIH Health Ransomware Attack

A ransomware attack halted operations across three of PIH’s hospitals.


Holidays are Prime Times for Healthcare Cyberattacks

A study found that 86 percent of organizations that experienced ransomware attacks were targeted on a holiday or weekend.


Hartford Healthcare Forms Partnership to Open Health Equity Clinic

The new clinic will open in January 2025.


UCHealth Reveals Plans for Memorial Hospital North Expansion

Construction on the patient tower is slated for 2026 with a projected opening to patients in 2029.


What Are 'Hospi-tels'?

Hospitals and hotels are partnering to better cater to patients and families.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.